©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2021; 13(10): 1351-1366
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1351
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1351
Liver transplantation for pediatric inherited metabolic liver diseases
Sunitha Vimalesvaran, Anil Dhawan, Paediatric Liver GI and Nutrition Center, King's College Hospital, London SE5 9RS, United Kingdom
Author contributions: Vimalesvaran S and Dhawan A wrote the review; Dhawan A provided guidance and insightful comments on the review.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Corresponding author: Anil Dhawan, BM BCh, MD, Professor, Paediatric Liver GI and Nutrition Center, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. anil.dhawan@kcl.ac.uk
Received: May 4, 2021
Peer-review started: May 4, 2021
First decision: June 15, 2021
Revised: June 23, 2021
Accepted: August 20, 2021
Article in press: August 20, 2021
Published online: October 27, 2021
Processing time: 171 Days and 11.9 Hours
Peer-review started: May 4, 2021
First decision: June 15, 2021
Revised: June 23, 2021
Accepted: August 20, 2021
Article in press: August 20, 2021
Published online: October 27, 2021
Processing time: 171 Days and 11.9 Hours
Core Tip
Core Tip: The decision for liver transplantation (LT) in liver based metabolic disorders (LBMDs) is not straightforward. As outcomes from pediatric LT continue to improve, transplantation is no longer merely life saving, but also potentially significantly improves the child’s quality of life. We herein discuss the clinical presentation, medical and surgical treatment for some of the common LBMDs. We provide a practical update on the indications, dilemmas and controversies for LT and the long-term outcomes for children with LBMDs.